{"id":22763,"date":"2015-11-11T13:05:02","date_gmt":"2015-11-11T12:05:02","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=22763"},"modified":"2015-11-11T13:05:02","modified_gmt":"2015-11-11T12:05:02","slug":"in-spagna-menarini-e-takeda-si-alleano-per-promuovere-tre-farmaci-per-il-diabete","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/in-spagna-menarini-e-takeda-si-alleano-per-promuovere-tre-farmaci-per-il-diabete\/","title":{"rendered":"In Spain, Menarini and Takeda team up to promote three diabetes medicines"},"content":{"rendered":"<p class=\"textoarticulo\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/img.europapress.net\/fotoweb\/fotonoticia_20151110175540_1280.jpg\" alt=\"\" width=\"284\" height=\"197\" \/>Menarini Spain and Takeda Pharmaceutical Spain signed a collaboration agreement in Barcelona to exclusively promote three new drugs for the treatment of type II diabetes in the country.<\/p>\n<p class=\"textoarticulo\">It is Vipidia (alogliptin) Vipdomet (Alogliptin and metformin) and Incresync (Alogliptin and pioglitazone). All c<span class=\"goog-text-highlight\">They contain the new active ingredient alogliptin, which is indicated to improve glycemic control in combination with other hypoglycemic drugs, diet and exercise in adult patients with type II diabetes, whose blood sugar is not adequately controlled with previous treatments.<\/span><\/p>\n<p class=\"textoarticulo\">Under the terms of the agreement, Menarini will have exclusive rights to promote and inform the scientific and medical community of the three drugs, while Takeda will distribute them.<\/p>\n<p class=\"textoarticulo\"><a href=\"http:\/\/www.elglobal.net\/noticias-medicamento\/2015-11-11\/industria-farmaceutica\/menarini-y-takeda-se-alian-para-promocionar-tres-medicamentos-para-la-diabetes-tipo-ii\/pagina.aspx?idart=948922\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Wednesday, November 11, 2015 \u2013 El GlobalNet<\/span><\/a><\/p>\n<p>Related news: <span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/www.fedaiisf.it\/en\/sanita-cara-lorenzin-perche-non-vuole-risparmiare\/\" target=\"_blank\">Healthcare: dear Lorenzin, why don&#039;t you want to save money?<\/a><\/span><\/p>\n<p class=\"site-block__title\"><a href=\"http:\/\/www.aboutpharma.com\/blog\/2015\/11\/10\/diabete-pazienti-italiani-raddoppiati-in-30-anni-e-15-mld-di-costi-per-il-ssn\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Diabetes: Italian patients doubled in 30 years and 15 billion in costs for the NHS<\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Menarini Spagna e Takeda Pharmaceutical Spagna hanno firmato a Barcellona un accordo di collaborazione per promuovere nel Paese in esclusiva tre nuovi farmaci per il trattamento del diabete di tipo II. \u00c8 Vipidia (alogliptin) Vipdomet (Alogliptin e metformina) e Incresync (Alogliptin e pioglitazone). Tutti contengono il nuovo principio attivo\u00a0alogliptin, che \u00e8 indicato per migliorare il &hellip;<\/p>","protected":false},"author":4,"featured_media":22770,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[47,54],"class_list":["post-22763","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-big-pharma","tag-marketing"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/22763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=22763"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/22763\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/22770"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=22763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=22763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=22763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}